home / stock / bioaf / bioaf news

BIOAF News and Press, Bioasis Technologies Inc From 07/09/20

Stock Information
Company Name: Bioasis Technologies Inc
Stock Symbol: BIOAF
Market: OTC
Website: bioasis.us
Menu
BIOAF BIOAF Quote BIOAF Short BIOAF News BIOAF Articles BIOAF Message Board
Get BIOAF Alerts

News, Short Squeeze, Breakout and More Instantly...
BIOAF - Bioasis and Chiesi Group to Host Webcast on July 16, 2020

BIOASIS TECHNOLOGIES INC . (“ Bioasis ”) (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“ BBB ”) and the t...
BIOAF - Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance

Deal provides Chiesi Group with worldwide, exclusive license to use Bioasis xB 3 TM platform for delivery of undisclosed enzymes in treatment of four lysosomal storage disorders. Under terms of the agreement, Bioasis will receive an upfront payment of US$3 million, additional potentia...

BIOAF - Bioasis Announces Conversion of Debenture Interest Into Equity

BIOASIS TECHNOLOGIES INC . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barr...

BIOAF - Bioasis Announces Analyst Coverage Initiated by Edison Group

BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSXV:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barrie...
BIOAF - Bioasis Completes Redemption of 15% Unsecured Debentures With Unanimous Debentureholder Approval

BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”) a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barrie...

BIOAF - Bioasis Announces Proposed Redemption of 15% Unsecured Debentures

BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain bar...

BIOAF - Growth Company Investor Presentations Now Available for On-Demand Viewing

NEW YORK , Feb. 24, 2020 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the February 20th conference are now available for on-demand viewing at VirtualInvestorConferences.com. ...
BIOAF - Bioasis to Present at the OTC Markets 2020 Virtual Investor Conference

GUILFORD, CONN ., Feb. 19, 2020 /PRNewswire/ -- Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier ("...

BIOAF - Live Investor Conference & Webinar: Growth Company CEOs Present February 20th

Live Investor Conference & Webinar: Growth Company CEOs Present February 20th Live Investor Conference & Webinar: Growth Company CEOs Present February 20th Canada NewsWire NEW YORK, Feb. 14, 2020 Company executives will share vision and answer audience questions a...

BIOAF - Bioasis to Present at the 22nd Annual BIO CEO Investor Conference and the OTC Markets 2020 Virtual Investor Conference

Bioasis Technologies Inc. (OTCQB:BIOAF)(TSX.V:BTI), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and th...
Previous 10 Next 10